Loading
UP
Uniphar plc Stock: price and insider trades · United Kingdom
No insider purchase over the last 90 days. The latest was filed 02 Dec 2024.
Uniphar plc: what insiders have been doing
Uniphar plc is a Healthcare & Pharma company. Its directors and officers file their transactions with RNS (LSE). Between 18 October 2025 and 18 October 2026, 4 insiders published 5 filings.
No insider bought on the market over the period, while 4 insiders filed 5 sales totalling €466k. Maurice Pratt filed the largest sale, €245k, on 16 May 2026.
Across the 831 companies tracked on its exchange, the median is 6 filings; at 5 filings, this issuer sits below that mark. Looking back to 2023, when coverage begins, insiders filed 8 purchases and 7 sales.
Typically, a trade is published a median of 2 days after it takes place. The legal deadline for notifying a trade is three business days (UK MAR). Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. Source: insider filings from RNS (LSE). Past trades are no guide to future returns.
Insider Decl.
15
Thresholds
n/a
Buy Volume
€38,609
8 ops. · all time
Sell Volume
€474,352
7 ops. · all time
Who traded when
BuySaleGerard Rabbette1 buy3 sales
Maurice Pratt3 sales
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Last declaration on 16 May 2026
Declarations15 total
50,000 shares@ €4.2545.9% of flowEuronext DublinISIN IE00BJ5FQX74IE:9569682
50,000 shares@ £4.28353.0% of flowEuronext DublinISIN IE00BJ5FQX74RNS:9569682
50,000 shares@ £0.04250.5% of flowEuronext DublinISIN IE00BJ5FQX74RNS:037cee2c-a2e9-473e-b304-30cf572b2ded
43,355 shares@ £0.03625.0% of flowEuronext DublinISIN IE00BJ5FQX74RNS:97b7064a-f44c-4b03-896a-121cf06a6717
100,000 shares@ £0.03812.1% of flowEuronext DublinISIN IE00BJ5FQX74RNS:9cc6356f-71a6-415d-8500-2b986118f46f
200,000 shares@ £0.03321.7% of flowEuronext DublinISIN IE00BJ5FQX74RNS:5650643
38,460 shares@ £0.02212.9% of flowEuronext DublinISIN IE00BJ5FQX74RNS:5451359
Canonical exit: 27 Feb 2025 (T+90)
490,012 shares@ £0.026642.6% of flowEuronext DublinISIN IE00BJ5FQX74RNS:5190546-0
Canonical exit: 18 Aug 2024 (T+90)
326,676 shares@ £0.0266100.0% of flowEuronext DublinISIN IE00BJ5FQX74RNS:5190546-1
Canonical exit: 18 Aug 2024 (T+90)
107,000 shares@ £0.02759.6% of flowEuronext DublinISIN IE00BJ5FQX74RNS:5143239-0
Canonical exit: 11 Jul 2024 (T+90)
5,000 shares@ £0.0275100.0% of flowEuronext DublinISIN IE00BJ5FQX74RNS:5143239-1
50,000 shares@ £0.023100.0% of flowEuronext DublinISIN IE00BJ5FQX74RNS:4929563
Canonical exit: 4 Jan 2024 (T+90)
87,500 shares@ £0.0230.5% of flowEuronext DublinISIN IE00BJ5FQX74RNS:4924241
Canonical exit: 3 Jan 2024 (T+90)
105,853 shares@ £0.0235100.0% of flowEuronext DublinISIN IE00BJ5FQX74RNS:4921197-1
Canonical exit: 31 Dec 2023 (T+90)
84,682 shares@ £0.02256.1% of flowEuronext DublinISIN IE00BJ5FQX74RNS:4921197-0
Canonical exit: 1 Jan 2024 (T+90)
15 of 15 declarations
About Uniphar plc
Uniphar plc is an international healthcare services group listed on the London Stock Exchange (FTSE 100/250/AIM) in the United Kingdom, trading under the ticker UPR. The company is headquartered operationally in Dublin, Ireland, and serves customers across Europe, North America, APAC and the Middle East/North Africa region. Its client base includes more than 200 multinational pharmaceutical, biotech and medical technology companies.
Uniphar has a long operating history, with the group highlighting more than 55 years of experience, which implies a foundation in the late 1960s. Over time, it has built an integrated healthcare platform spanning several parts of the value chain. The business is structured into three core divisions: Uniphar Pharma, Uniphar Medtech, and Uniphar Supply Chain & Retail. This mix combines higher-value services with distribution-led activities, creating a differentiated model centered on access, compliance, logistics and commercial execution.
Read moreShow less
Uniphar Pharma brings together Access, Medical and Commercial capabilities. These include expanded access programs, medical affairs, regulatory and pharmacovigilance support, market access, launch support, commercial services and distribution. Uniphar Medtech focuses on European medical device distribution and related services, while Uniphar Supply Chain & Retail remains an important platform for pharmaceutical supply chain and retail activities in Ireland. The group does not primarily sell its own branded medicines; instead, it provides critical infrastructure and services that help manufacturers bring products to market and improve patient access.
From a competitive standpoint, Uniphar is positioned as a specialist partner for pharma, medtech and biotech companies seeking to manage complex launches, multi-country access requirements and specialist distribution needs. Its value proposition is built around end-to-end service integration and a broad geographic reach, with the company describing operations across more than 160 countries. This makes it a useful partner for innovators that need regulatory, commercial and supply chain support rather than a pure-play wholesaler.
Recent developments reinforce that strategic direction. In 2025, Uniphar rebranded its On Demand business as Uniphar | Global Sourcing, sharpening its global pharmaceutical sourcing platform and extending its capabilities through strategically located facilities in the US and Europe. In 2026, the group also announced an exclusive European distribution agreement for LYMPHIR™ with Citius Oncology, underscoring its role in facilitating access to complex therapies and supporting international commercialization pathways.
For investors, Uniphar is best viewed as a healthcare services and distribution specialist with defensive characteristics, exposed to the structural growth of outsourced pharma services, specialty distribution and access solutions in the United Kingdom-listed market on the London Stock Exchange (FTSE 100/250/AIM).
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations